PCR Technologies Companies

The PCR technologies market is projected to reach USD 21.43 billion by 2031 from USD 15.55 billion in 2026, at a CAGR of 6.6% during 2026–2031. Market growth is driven by rising demand for molecular diagnostics, precision medicine, and rapid nucleic acid detection, along with advances in qPCR, digital PCR, multiplexing, and automated workflows. Expanding applications across clinical diagnostics, genomics, biopharmaceuticals, and disease surveillance further support demand. However, high equipment costs, technical complexity, skilled-labor requirements, and regulatory hurdles may constrain adoption.

Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Lonza (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Bioneer Corporation (South Korea), Revvity (US), Hologic Inc. (US), Sansure Biotech Inc. (China), Becton, Dickinson and Company (US), and Analytik Jena AG (Germany).

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US): Thermo Fisher Scientific is a leading PCR technology provider offering a broad portfolio of PCR instruments, reagents, consumables, software, and digital PCR solutions. Its QuantStudio Absolute Q Digital PCR System strengthens its dPCR capabilities with high-accuracy absolute quantification, simplified workflows, rapid time to results, and modular automation for high-throughput applications. The platform supports growing applications in oncology, gene expression, cell and gene therapy, copy number variation, NGS library quantification, rare mutation detection, and environmental surveillance, reinforcing the company's position across research and molecular testing applications.

F. Hoffmann-La Roche Ltd. (Switzerland): Roche is a leading provider of PCR and molecular diagnostics, with an integrated portfolio spanning high-throughput laboratory testing, open molecular solutions, syndromic testing, and point-of-care diagnostics. Its PCR ecosystem includes the cobas 5800, LightCycler PRO, cobas eplex, and cobas liat platforms, which address diverse testing volumes and workflow requirements. The company's focus on automation, sample-to-answer workflows, multiplex testing, assay flexibility, connectivity, and decentralized PCR testing strengthens its competitive position in clinical diagnostics and supports demand for faster, standardized molecular testing.

Bio-Rad Laboratories, Inc. (US): Bio-Rad Laboratories is a leading PCR technology company with a comprehensive portfolio spanning conventional PCR, real-time PCR, digital PCR, reagents, consumables, and software. Its portfolio includes thermal cyclers, CFX real-time PCR systems, and Droplet Digital PCR (ddPCR) systems, supporting applications from routine DNA amplification and quantitative analysis to highly sensitive absolute quantification. The company's continued focus on ddPCR, multiplex real-time PCR, automation compatibility, and advanced PCR platforms positions it strongly across research, biotechnology, diagnostics, environmental testing, and educational applications.

Related Reports:

PCR Technologies Market by Technology (qPCR, dPCR, Multiplex, RT-PCR), Product (Instruments, Reagents & Consumables, Software), Application (Genotyping, Diagnostics, Environmental), End User (Hospital, Academia, Pharma-Biopharma) – Global forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]